Posted inNews and Updates
NeuroSense CEO Shares Strategic Roadmap for 2024
NeuroSense Therapeutics outlines its strategic goals for ALS research and PrimeC clinical development in a new update for investors and stakeholders.
Posted inNews and Updates
Khartis Therapeutics Secures $95M for Thyroid Eye Disease
Khartis Therapeutics launches with $95M to develop an oral pill for Thyroid Eye Disease, aiming to challenge existing biologic infusions with new tech.
Posted inNews and Updates
Karyopharm Advances Myelofibrosis Drug Pipeline
Karyopharm reports Q2 2026 financial results, highlighting major strides toward an sNDA submission for a novel myelofibrosis treatment. Learn more.
Posted inNews and Updates
Sagimet Biosciences Phase 3 Trial Set for 2026 Launch
Sagimet Biosciences confirms its Phase 3 trial for denifanstat is on track for 2026, marking a major step forward in treating MASH and metabolic disease.
Posted inNews and Updates
Sumitomo Pharma Initiates Phase I/IIa Trial for DSP-3077
Sumitomo Pharma has officially dosed the first patient in a Phase I/IIa trial for DSP-3077. Learn about the study's scope, safety goals, and clinical aims.
Posted inNews and Updates
FDA Updates Cancer Trial Rules to Expand Patient Access
The FDA has released new guidance to broaden clinical trial eligibility for cancer patients, aiming to increase diversity and speed up drug development.
Posted inNews and Updates
Kupando Initiates Phase 1 Clinical Trial for Novel Therapy
Kupando has commenced its first-in-human Phase 1 clinical trial. Discover the latest updates on this investigational therapy’s safety and development path.
Posted inNews and Updates
The Hidden Costs of Clinical Trial Infrastructure
Are high ROI claims in clinical trials ignoring site-level costs? Discover why sustainable infrastructure is essential for the future of drug development.
Posted inNews and Updates
Nafamostat Gains KDIGO Endorsement Amid CRRT Trial Progress
Nafamostat receives key KDIGO endorsement for CRRT as Talphera nears completion of the NEPHRO trial. Discover how this shift impacts ICU patient care.
Posted inNews and Updates
ArkBio’s AK0406 Influenza Drug Enters Clinical Trials
ArkBio has launched clinical trials for its new influenza drug, AK0406. Learn how this antiviral candidate could impact future respiratory infection care.